Short answer
SELLAS Life Sciences Group, Inc. (SLS) filed its Q3 2025 10-Q quarterly report on Nov 12, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$7M
- +4.5% YoY · −2.9% QoQ
- EPS (diluted)
- −$0.07
- +22.2% YoY · −16.7% QoQ
Source: XBRL data from the SELLAS Life Sciences Group, Inc. (SLS) Q3 2025 10-Q on SEC EDGAR. USD.
SELLAS Life Sciences Group, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability or margin percentages disclosed in provided text
- REGAL Phase 3 study: 126 patients enrolled, final analysis at 80 deaths
- Potential future 3D Medicines milestones $191.5M, with $10.5M received as of March 15, 2025
Risk Factors
- No material risk-factor changes disclosed; 2024 Annual Report risks carried forward
- Additional unknown or currently immaterial risks could adversely affect business, financial condition, results, and stock price
- September 11, 2025 and October 27, 2025 inducement warrants signal new equity-linked financing activity
- No unregistered equity sales, senior-security defaults, or Rule 10b5-1 trading-plan changes reported for quarter ended September 30, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other SELLAS Life Sciences Group, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.